New batch available — All COAs updated  ·  Free shipping on orders over $150
Home/Catalog/Growth Hormone Axis/CJC-1295 (No DAC)
GH Series CJC-1295 (No DAC) 10 mg
Lot CB26-04-007MFG 04/2026

About CJC-1295 (No DAC)

CJC-1295 (no DAC), also referred to in the literature as Modified GRF 1-29, is a 29-residue analog of human growth-hormone-releasing hormone (GHRH 1-29) carrying four amino-acid substitutions designed to confer enzymatic stability.

Research interest centers on GHRH-receptor signaling and the kinetics of GH-releasing factor analogues. The compound has been investigated in pre-clinical models of growth-hormone insufficiency and as a comparator to native GHRH 1-29.

Each lot is independently verified for purity (HPLC + ESI-MS) and endotoxin (LAL kinetic chromogenic) before listing.

Identity & Specifications

Sequence
YADAIFTQSYRKVLAQLSARKLLQDIMSR
Length
29 residues (tetrasubstituted)
Formula
C₁₅₂H₂₅₂N₄₄O₄₂
Mol. weight
3367.94 g/mol
CAS
863288-34-0
PubChem
57396696
Purity (HPLC)
≥ 98.8%
Endotoxin (LAL)
0.20 EU/mg
Reconstitution
Bacteriostatic water
Storage
−20°C, sealed

Certificate of Analysis · Lot CB26-04-007

ParameterMethodSpecResult
IdentityESI-MSConformsPass
PurityHPLC-UV 220 nm≥ 98.0%98.8%
EndotoxinLAL kinetic< 0.5 EU/mg0.20 EU/mg
BioburdenMicrobial count< 100 CFU/g< 10 CFU/g
Water contentKarl Fischer≤ 6.0%4.05%
AppearanceVisualWhite lyophilized cakeConforms
Issued 2026-04-12Analyst K. Vance
Download full certificate (PDF)

Selected References

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab, 2006.
  2. Mayo KE, et al. Growth hormone-releasing hormone: synthesis and signaling. Recent Prog Horm Res, 1995.
  3. Frohman LA, Kineman RD. Growth hormone-releasing hormone and pituitary development. Endocrinology, 1999.
  4. Veldhuis JD, et al. Pulsatile GH secretion: theoretical perspectives. Endocr Rev, 1991.
  5. Khorram O, et al. GHRH analogs: structure-activity relationships. Trends Endocrinol Metab, 1997.

Recent Research Highlights

2006
GHRH Analog Pharmacokinetics
Teichman et al. · J Clin Endocrinol Metab
Characterized the half-life and GH-pulse response of GHRH analog families in clinical research.
2005
GHRH Receptor Signaling
Mayo et al.
Reviewed GHRH-receptor mechanisms and analogue design.
Comparator Studies
Various
Used as a comparator molecule in studies of native GHRH 1-29 and longer-acting derivatives.
Combination Research
Various
Often paired with GHRP analogs in models of synergistic GH release.
3rd Party Tested
Independent lab
≥98%
HPLC Purity
+ ESI-MS
LAL
Endotoxin
LAL kinetic
§
Lot-traceable
In COA library

§ Research-Use Compliance

This compound is supplied by Crescent Bioresearch LLC for laboratory research and pre-clinical use only. It is not a drug, dietary supplement, food, or cosmetic, and has not been approved by the U.S. Food and Drug Administration for human or veterinary administration, diagnosis, treatment, or prevention of any condition.

The pharmacological, toxicological, and stability properties of this compound have not been fully studied. It must therefore be handled only by personnel trained in laboratory safety practices.

The purchaser bears sole responsibility for ensuring that all handling, storage, and intended use comply with applicable local, state, and federal regulations. Full terms are set out in the RUO Disclaimer and Terms of Service.